Sinovac Biotech Ltd.
SVA · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 14.47% | -20.63% | 0.28% |
| EV / EBITDA | 0.00 | 12.18 | -35.36 | 3.56 |
| Quality | ||||
| ROIC | 0.00% | -2.50% | 3.43% | -5.39% |
| Gross Margin | 0.00% | 100.00% | -34.19% | -53.35% |
| Cash Conversion Ratio | -1.25 | -2.36 | -0.41 | -1.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 108.82% | 254.60% | 339.35% | 357.68% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 36.19 | -66.33 | 4.21 |
| Interest Coverage | 0.00 | -61.65 | -1,630.95 | -1,682.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.03 | 2.38 |
| Cash Conversion Cycle | 0.00 | 131.76 | 16.60 | 229.25 |